This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Feroze Ujjainwalla
Director of Business Development & Licensing at Merck

Profile

Dr. Ujjainwalla joined Merck in 1996 having completed a 2 year post-doctoral appointment at The University of Texas at Austin in Austin, Texas; and his PhD in 1993 at The Imperial College in London, UK. During his career at Merck, he has risen through the ranks from Senior Research Chemist to Executive Director of Chemistry and is currently Director of Business Development & Licensing (BD&L).

In Chemistry, he has worked on a variety of targets (Enzymes, Ion Channels, GPCRs, Nuclear Hormone Receptors) across a number of disease areas (Asthma, Atherosclerosis, COPD, Diabetes, Endocrine, Hypertension, Obesity, Oncology, Pain) in all phases of discovery and development. He has led programs in Target Validation, Lead Identification, Lead Optimization, Preclinical Development and Clinical Development, having delivered: 8 preclinical development candidates of which 3 proceeded to clinical trials; and 7 unambiguous mechanism No-Go’s.

In BD&L, he has been responsible for search, scientific evaluation and execution of licensing deals and strategic partnerships in the area of Enabling Technologies for Chemistry, Pharmacology, Safety Assessment as well Pharmacokinetics and Drug Metabolism. He has been instrumental in establishing a number of recent deals in the area of protein engineering, imaging, screening, computational chemistry, peptide drug discovery and chemical biology.

Throughout his professional career, Dr. Ujjainwalla has led or participated in a number of departmental, cross-functional and strategic initiatives spanning recruiting, talent management, networking, licensing, business operations, scientific operations, therapeutic area review, symposia and animal care & use. He is author/co-author of 35 publications and 50 issued patents/patent applications.

Agenda Sessions

  • Panel Discussion: Deals that matter: Partnering with platform technologies: Trends, models and challenges.

    1:30am